CLL/SLL
Conditions
Brief summary
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Interventions
DRUGBTK inhibitor
BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years; * Patients with a confirmed diagnosis of CLL/SLL; * Received BTK inhibitor treatment between February 2023 and February 2024.
Exclusion criteria
* Patients with other types of lymphoma; * Cases deemed unsuitable for inclusion in this study by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient characteristics of those receiving BTKi treatment | up to one year | Describe the patient characteristics of those receiving BTKi treatment, including age, gender, etc |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall response rate | up to one year | Assessed according to the iwCLL2018 criteria |
| Incidence of adverse reactions | up to one year | Assessed according to the CTCAE 5.0 criteria |
Countries
China
Contacts
Primary ContactHuayuan Zhu, MD
Outcome results
None listed